Histofy, a leading developer of transparent AI solutions for pathology, proudly introduces MitPro, its cutting-edge AI tool designed for advanced mitosis profiling—a critical component in cancer grading.
Birmingham, UK (31st January 2024) –Histofy, a pioneering startup developing AI tools for pathology, unveils MitPro, a solution tailored for the comprehensive counting and profiling of mitosis. The quantification of cells undergoing division within pathology slides, known as mitotic figures, serves as a key indicator of cancer aggressiveness, or grade. This information is instrumental in guiding optimal patient treatment, making mitosis assessment a crucial task. However, traditional mitosis counting is both time-consuming and plagued by poor reproducibility.
Histofy addresses these challenges with MitPro, an AI solution that streamlines and extends mitosis profiling. The tool enhances the current standard of care for grading various cancers, such as breast cancer and sarcomas, by accurately identifying dividing cancer cells. In this context, an elevated count of dividing cells indicates a fast-growing or highly aggressive tumour. Conventionally, pathologists perform this counting manually, but due to time constraints, it is limited to a small portion of the tumour. With the power of AI, MitPro can count these dividing cells more accurately and over the entire tumour, providing a better indication for the cancer grade and leading to enhanced patient care and biomarker identification.
Prof Snead, Chief Medical Officer at Histofy, said: “Despite its paramount importance, mitosis assessment can be laborious and suffers from reproducibility issues. We are thrilled to introduce MitPro, a solution that not only improves current practice, but also enables comprehensive profiling of cell proliferation across the entire tumour.”
"MitPro not only improves current practice, but also enables comprehensive profiling of cell proliferation across the tumour"
Integration with pathology workflows
To facilitate the widespread adoption of AI in practical settings, Histofy is integrating with established pathology image management systems, including Sectra.
Dr Simon Graham, Chief Technology Officer at Histofy, said: “By integrating with Sectra, we enable users of the Sectra Digital Pathology Solution to integrate MitPro as part of their regular workflow. We remain dedicated to integrating our technology with various image management systems to broaden the accessibility of our AI tools in real-world practice.”
Histofy is presently engaged in the validation of MitPro with early adopters of the tool to showcase its practical utility. While the tool is currently designated for research use only, Histofy is currently working towards CE-mark certification under IVDR.
About Histofy
Histofy develops transparent AI solutions for computational pathology to improve the treatment of various diseases, such as cancer. With a focus on tissue-based diagnostics and prognostics, our technology complements pathologists to help deliver better patient care.
With leading research spanning over two decades, our team thoroughly understands the process of technology development, from concept to validation, placing us in prime position to bring cutting-edge AI to clinical and pharmaceutical settings.
